GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » EBITDA per Share

Alder BioPharmaceuticals (Alder BioPharmaceuticals) EBITDA per Share : $-4.08 (TTM As of Jun. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals EBITDA per Share?

Alder BioPharmaceuticals's EBITDA per Share for the three months ended in Jun. 2019 was $-0.63. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2019 was $-4.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Alder BioPharmaceuticals's EBITDA per Share or its related term are showing as below:

ALDR's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 6
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Alder BioPharmaceuticals's EBITDA for the three months ended in Jun. 2019 was $-52.90 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Alder BioPharmaceuticals EBITDA per Share Historical Data

The historical data trend for Alder BioPharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals EBITDA per Share Chart

Alder BioPharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBITDA per Share
Get a 7-Day Free Trial 0.32 -2.11 -3.19 -4.89 -4.06

Alder BioPharmaceuticals Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -0.82 -1.09 -1.54 -0.63

Alder BioPharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Alder BioPharmaceuticals's EBITDA per Share for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA per Share(A: Dec. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=-276.455/68.099
=-4.06

Alder BioPharmaceuticals's EBITDA per Share for the quarter that ended in Jun. 2019 is calculated as

EBITDA per Share(Q: Jun. 2019 )
=EBITDA/Shares Outstanding (Diluted Average)
=-52.899/83.480
=-0.63

EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alder BioPharmaceuticals  (NAS:ALDR) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Alder BioPharmaceuticals EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
11804 North Creek Parkway South, Bothell, WA, USA, 98011
Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.
Executives
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S 10 percent owner 9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno director
Carlos Campoy officer: Chief Financial Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby director, officer: President and CEO 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston director C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green director 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc director ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton officer: Chief Business Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter officer: Interim Chief Medical Officer C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Headlines

From GuruFocus